Recommendations for the management of advanced and metastatic renal cell carcinoma: joint consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Poon, D M C; Chan, C K; Chan, K; Chu, W H; Kwong, P W K; Lam, W; Law, K S; Lee, E K C; Liu, P L; Sze, H C K; Wong, J H M; Chan, E S Y

Poon, D M C; Chan, C K; Chan, K; Chu, W H; Kwong, P W K; Lam, W; Law, K S; Lee, E K C; Liu, P L; Sze, H C K; Wong, J H M; Chan, E S Y.

Affiliation

Poon DMC; Hong Kong Society of Uro-Oncology, Hong Kong.
Chan CK; Hong Kong Urological Association, Hong Kong.
Chan K; Hong Kong Society of Uro-Oncology, Hong Kong.
Chu WH; Hong Kong Urological Association, Hong Kong.
Kwong PWK; Hong Kong Society of Uro-Oncology, Hong Kong.
Lam W; Hong Kong Urological Association, Hong Kong.
Law KS; Hong Kong Society of Uro-Oncology, Hong Kong.
Lee EKC; Hong Kong Society of Uro-Oncology, Hong Kong.
Liu PL; Hong Kong Urological Association, Hong Kong.
Sze HCK; Hong Kong Society of Uro-Oncology, Hong Kong.
Wong JHM; Hong Kong Urological Association, Hong Kong.
Chan ESY; Hong Kong Urological Association, Hong Kong.

Hong Kong Med J ; 28(6): 475-481, 2022 12.

Article in En | MEDLINE | ID: mdl-35815480

Subject(s)

Carcinoma, Renal Cell; Kidney Neoplasms; Humans; Male; Carcinoma, Renal Cell/therapy; Kidney Neoplasms/therapy; Hong Kong/epidemiology; Consensus; Societies, Medical

Key words

Carcinoma, renal cell; Consensus; Immune checkpoint inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limits: Humans / Male Country/Region as subject: Asia Language: En Journal: Hong Kong Med J Journal subject: MEDICINA Year: 2022 Type: Article Affiliation country: Hong Kong

Fulltext

XML

PubMed Links

Search on Google